Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.

Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ, Crispin M, Montefiori DC, Wilson IA, Ward AB, Sanders RW, Klasse PJ, Moore JP.

J Virol. 2019 Feb 5;93(4). pii: e01656-18. doi: 10.1128/JVI.01656-18. Print 2019 Feb 15.

PMID:
30487280
2.

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.

Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC, van Gils MJ, Bricault CA, Barouch DH, Crotty S, Silvestri G, Kasturi S, Pulendran B, Wilson IA, Montefiori DC, Sanders RW, Ward AB, Moore JP.

PLoS Pathog. 2018 Feb 23;14(2):e1006913. doi: 10.1371/journal.ppat.1006913. eCollection 2018 Feb.

3.

cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.

Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens AJ, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E, Desaire H, Crispin M, Wilson IA, Sanders RW, Hassell T, Ward AB, Moore JP.

Biotechnol Bioeng. 2018 Apr;115(4):885-899. doi: 10.1002/bit.26498. Epub 2017 Dec 11.

4.

Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization.

Torrents de la Peña A, Julien JP, de Taeye SW, Garces F, Guttman M, Ozorowski G, Pritchard LK, Behrens AJ, Go EP, Burger JA, Schermer EE, Sliepen K, Ketas TJ, Pugach P, Yasmeen A, Cottrell CA, Torres JL, Vavourakis CD, van Gils MJ, LaBranche C, Montefiori DC, Desaire H, Crispin M, Klasse PJ, Lee KK, Moore JP, Ward AB, Wilson IA, Sanders RW.

Cell Rep. 2017 Aug 22;20(8):1805-1817. doi: 10.1016/j.celrep.2017.07.077.

5.

Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers.

Ringe RP, Ozorowski G, Rantalainen K, Struwe WB, Matthews K, Torres JL, Yasmeen A, Cottrell CA, Ketas TJ, LaBranche CC, Montefiori DC, Cupo A, Crispin M, Wilson IA, Ward AB, Sanders RW, Klasse PJ, Moore JP.

J Virol. 2017 Jul 12;91(15). pii: e00677-17. doi: 10.1128/JVI.00677-17. Print 2017 Aug 1.

6.

Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.

Klasse PJ, LaBranche CC, Ketas TJ, Ozorowski G, Cupo A, Pugach P, Ringe RP, Golabek M, van Gils MJ, Guttman M, Lee KK, Wilson IA, Butera ST, Ward AB, Montefiori DC, Sanders RW, Moore JP.

PLoS Pathog. 2016 Sep 14;12(9):e1005864. doi: 10.1371/journal.ppat.1005864. eCollection 2016 Sep.

7.

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP.

Science. 2015 Jul 10;349(6244):aac4223. doi: 10.1126/science.aac4223. Epub 2015 Jun 18.

8.

A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.

Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N, Derking R, Kim HJ, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, Julien JP, Burton DR, Wilson IA, Sanders RW, Klasse PJ, Ward AB, Moore JP.

J Virol. 2015 Mar;89(6):3380-95. doi: 10.1128/JVI.03473-14. Epub 2015 Jan 14.

9.

Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies.

Chung NP, Matthews K, Kim HJ, Ketas TJ, Golabek M, de Los Reyes K, Korzun J, Yasmeen A, Sanders RW, Klasse PJ, Wilson IA, Ward AB, Marozsan AJ, Moore JP, Cupo A.

Retrovirology. 2014 Apr 25;11:33. doi: 10.1186/1742-4690-11-33.

10.

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP.

PLoS Pathog. 2013 Sep;9(9):e1003618. doi: 10.1371/journal.ppat.1003618. Epub 2013 Sep 19.

11.

Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220.

Fetherston SM, Geer L, Veazey RS, Goldman L, Murphy DJ, Ketas TJ, Klasse PJ, Blois S, La Colla P, Moore JP, Malcolm RK.

J Antimicrob Chemother. 2013 Feb;68(2):394-403. doi: 10.1093/jac/dks415. Epub 2012 Oct 28. Erratum in: J Antimicrob Chemother. 2013 Jun;68(6):1451.

12.

Enhancement of α-helix mimicry by an α/β-peptide foldamer via incorporation of a dense ionic side-chain array.

Johnson LM, Mortenson DE, Yun HG, Horne WS, Ketas TJ, Lu M, Moore JP, Gellman SH.

J Am Chem Soc. 2012 May 2;134(17):7317-20. doi: 10.1021/ja302428d. Epub 2012 Apr 23.

13.

Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.

Anastassopoulou CG, Ketas TJ, Sanders RW, Klasse PJ, Moore JP.

Virology. 2012 Jul 5;428(2):86-97. doi: 10.1016/j.virol.2012.03.008. Epub 2012 Apr 19.

14.

Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.

Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJ, Doyle LA, Rasmussen KK, Goldman L, Ketas TJ, Moore JP.

Antimicrob Agents Chemother. 2012 May;56(5):2251-8. doi: 10.1128/AAC.05810-11. Epub 2012 Feb 13.

15.

Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Ketas TJ, Holuigue S, Matthews K, Moore JP, Klasse PJ.

Virology. 2012 Jan 5;422(1):22-36. doi: 10.1016/j.virol.2011.09.019. Epub 2011 Oct 22.

16.

Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.

Anastassopoulou CG, Ketas TJ, Depetris RS, Thomas AM, Klasse PJ, Moore JP.

Virology. 2011 Apr 25;413(1):47-59. doi: 10.1016/j.virol.2010.12.052. Epub 2011 Feb 26.

17.

Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.

Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP.

J Infect Dis. 2010 Sep 1;202(5):739-44. doi: 10.1086/655661.

18.

Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.

Horne WS, Johnson LM, Ketas TJ, Klasse PJ, Lu M, Moore JP, Gellman SH.

Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14751-6. doi: 10.1073/pnas.0902663106. Epub 2009 Aug 17.

19.

HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits.

Xu W, Santini PA, Sullivan JS, He B, Shan M, Ball SC, Dyer WB, Ketas TJ, Chadburn A, Cohen-Gould L, Knowles DM, Chiu A, Sanders RW, Chen K, Cerutti A.

Nat Immunol. 2009 Sep;10(9):1008-17. doi: 10.1038/ni.1753. Epub 2009 Aug 2.

20.

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP.

Virology. 2009 Jun 20;389(1-2):108-21. doi: 10.1016/j.virol.2009.04.001. Epub 2009 May 2.

21.

Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.

Pugach P, Ray N, Klasse PJ, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP.

Virology. 2009 May 10;387(2):296-302. doi: 10.1016/j.virol.2009.02.044. Epub 2009 Mar 20.

22.

Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.

Ingallinella P, Bianchi E, Ladwa NA, Wang YJ, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD, Pessi A.

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5801-6. doi: 10.1073/pnas.0901007106. Epub 2009 Mar 18.

23.

Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.

Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5318-23. doi: 10.1073/pnas.0811713106. Epub 2009 Mar 16.

24.

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.

Pugach P, Ketas TJ, Michael E, Moore JP.

Virology. 2008 Aug 1;377(2):401-7. doi: 10.1016/j.virol.2008.04.032. Epub 2008 Jun 2.

25.

N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.

Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP.

Virology. 2008 Mar 1;372(1):187-200. Epub 2007 Nov 26.

26.

Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.

Ketas TJ, Kuhmann SE, Palmer A, Zurita J, He W, Ahuja SK, Klasse PJ, Moore JP.

Virology. 2007 Aug 1;364(2):281-90. Epub 2007 Apr 10.

27.

Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.

Ketas TJ, Schader SM, Zurita J, Teo E, Polonis V, Lu M, Klasse PJ, Moore JP.

Virology. 2007 Aug 1;364(2):431-40. Epub 2007 Apr 10.

28.

Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.

Deng Y, Zheng Q, Ketas TJ, Moore JP, Lu M.

Biochemistry. 2007 Apr 10;46(14):4360-9. Epub 2007 Mar 20.

PMID:
17371053
29.

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.

Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, Kuhmann SE.

Virology. 2007 Apr 25;361(1):212-28. Epub 2006 Dec 12.

30.

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.

Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP.

Nature. 2005 Nov 3;438(7064):99-102. Epub 2005 Oct 30.

PMID:
16258536
31.

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC.

Antimicrob Agents Chemother. 2004 Feb;48(2):423-9.

32.

Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M Jr, Kunstman K, Kuhmann SE, Marx PA, Lifson JD, Dufour J, Mefford M, Pandrea I, Wolinsky SM, Doms RW, DeMartino JA, Siciliano SJ, Lyons K, Springer MS, Moore JP.

J Exp Med. 2003 Nov 17;198(10):1551-62.

33.

Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.

Ketas TJ, Klasse PJ, Spenlehauer C, Nesin M, Frank I, Pope M, Strizki JM, Reyes GR, Baroudy BM, Moore JP.

AIDS Res Hum Retroviruses. 2003 Mar;19(3):177-86.

PMID:
12689409
34.

Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.

Ketas TJ, Frank I, Klasse PJ, Sullivan BM, Gardner JP, Spenlehauer C, Nesin M, Olson WC, Moore JP, Pope M.

J Virol. 2003 Feb;77(4):2762-7.

35.

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC.

J Virol. 2001 Jan;75(2):579-88.

36.

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.

Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, Trkola A, Klotman ME, Maddon PJ, Olson WC, Israel RJ.

J Infect Dis. 2000 Jul;182(1):326-9. Epub 2000 Jun 30.

PMID:
10882617

Supplemental Content

Loading ...
Support Center